Search

Your search keyword '"McGregor B"' showing total 3 results
Start Over Author "McGregor B" Journal value in health
3 results on '"McGregor B"'

1. PCN53 Grade 3/4 Adverse Event (AE) Costs of Nivolumab Plus Ipilimumab (N+I) Versus Nivolumab Plus Cabozantinib (N+C) and Pembrolizumab Plus Axitinib (P+A) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC)

Author

McGregor, B., primary, Geynisman, D., additional, Burotto, M., additional, Porta, C., additional, Suarez, C., additional, Bourlon, M.T., additional, Stwalley, B., additional, Du, E.X., additional, Gu, C., additional, Sendhil, S., additional, Betts, K.A., additional, Huo, S., additional, and Choueiri, T.K., additional

Published
2021
Full Text
View/download PDF

2. PCN92 Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib (N+C) Versus Sunitinib (S) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC)

Author

Geynisman, D., primary, McGregor, B., additional, Burotto, M., additional, Porta, C., additional, Suarez, C., additional, Bourlon, M.T., additional, Stwalley, B., additional, Du, E.X., additional, Gu, C., additional, Yang, X., additional, Betts, K.A., additional, Huo, S., additional, and Choueiri, T.K., additional

Published
2021
Full Text
View/download PDF

3. PCN22 CLINICAL HETEROGENEITY AMONG FIRST-LINE SUNITINIB PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) CATEGORIZED AS INTERMEDIATE RISK (IR) GROUP ACCORDING TO THE INTERNATIONAL MRCC DATABASE CONSORTIUM (IMDC) RISK MODEL

Author

Huynh, L., primary, Wells, J.C., additional, Graham, J., additional, Steinharter, J., additional, McGregor, B., additional, Donskov, F., additional, Bjarnason, G.A., additional, Vaishampayan, U., additional, Hansen, A., additional, Iafolla, M., additional, Zanotti, G., additional, Chang, R., additional, Cheng, W.Y., additional, Duh, M.S., additional, and Heng, D.Y.C., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results